By Longeveron
MIAMI, May 09, 2023 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced new long-term follow-up data from the Company’s ELPIS I trial of Lomecel-BTM for patients with hypoplastic left heart syndrome (HLHS).
The data showed that 100% of the 10 patients who participated in the ELPIS I trial survived and remained heart transplant-free for up to 5 years of age after receiving Lomecel-BTM during their Stage 2 surgery. To-date All 10 patients enrolled in the study have been monitored for at least 3.5 years after treatment with Lomecel-BTM. All patients are more than 4 years of age, with 2 being 5 years of age, and additional long-term follow-up is ongoing in the ELPIS I participants. Historical results have shown that children with HLHS have approximately 20% mortality by 5 years.
In addition, about three years after the Stage 2 surgery, most of these patients undergo the third palliative surgery, which is the last of the standard sequence of surgeries that comprises the current standard of care for HLHS. To-date, 5 of 5 of the eligible patients from the ELPIS I trial have already undergone this third surgery.
